2653 completed, 439 unknown, 380 recruiting, 361 terminated. 4438 Phase 3, 506 Phase 2.
Follow Skin and Connective Tissue Diseases: new trials by email Literature Review of Skin and Connective Tissue Diseases trials Research Report on Skin and Connective Tissue Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis Acetyl Salicylic Acid (ASA), Placebo - Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS) | Phase 3 | Not yet recruiting | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 120 | 2027-10-01 | 2026-10-30 |
| Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT Trametinib - HCM, Noonan Syndrome and Other Rasopathy | Phase 3 | Not yet recruiting | Carelon Research | 25 | 2027-08-01 | 2026-09-14 |
| Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer Locoregional Radiotherapy With Internal Mammary Node Irradiation, Locoregional Radiotherapy Without Internal Mammary Node Irradiation - Breast Neoplasms | Phase 3 | Not yet recruiting | Mahidol University | 1760 | 2027-07-01 | 2026-11-04 |
| Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Pfizer | 90 | 2027-05-01 | 2026-09-16 |
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) garetosmab - Fibrodysplasia Ossificans Progressiva, FOP | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 18 | 2027-02-02 | 2026-10-20 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. Minoxidil oral solution, Placebo oral solution - Androgenetic Alopecia, Androgenetic Alopecia (AGA) | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 372 | 2027-01-31 | 2026-11-06 |
| Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) Radiation Therapy, Standard of Care Radiation Therapy, No Intervention - Breast Cancer | Phase 3 | Not yet recruiting | NRG Oncology | 5270 | 2027-01-30 | 2026-09-30 |
| Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss DA-005, Topical minoxidil 5%, DA-002 - Androgenetic Alopecia, Female Pattern Baldness | Phase 3 | Withdrawn | Applied Biology, Inc. | 2027-01-15 | 2026-11-02 | |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Placebo, Zasocitinib - Psoriatic Arthritis | Phase 3 | Not yet recruiting | Takeda | 644 | 2027-01-11 | 2026-10-27 |
| Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) Sodium Stibogluconate (SSG), Miltefosine, Miltefosine + Paromomycin - Cutaneous Leihmaniasis | Phase 3 | Not yet recruiting | Institute of Tropical Medicine, Belgium | 900 | 2027-01-01 | 2026-03-10 |
| Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease BOTOX INJECTION - Buerger Disease, Raynaud Syndrome | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 8 | 2027-01-01 | 2026-07-23 |
| Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN) N1087, Placebo - Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 372 | 2027-01-01 | 2026-11-04 |
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan Dexamethasone, antiemetic premedication, T-DXd - Breast Cancer, Interstitial Lung Disease (ILD) | Phase 3 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 244 | 2026-12-20 | 2026-10-19 |
| A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment Giredestrant - Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 1500 | 2026-12-11 | 2026-11-03 |
| ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months. Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone - Rheumatic Fever, Rheumatic Heart Disease in Children | Phase 3 | Not yet recruiting | Starship Child Health, Te Toka Tumai Auckland | 600 | 2026-12-01 | 2026-10-07 |
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial Botulinum Toxin Type A, Autologous Nanofat Injection - Androgenetic Alopecia | Phase 2 / Phase 3 | Not yet recruiting | Sherief Ayman Hussein Shaamash | 40 | 2026-12-01 | 2026-10-07 |
| Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) Tralesinidase alfa (TA) - MPS IIIB | Phase 3 | Not yet recruiting | Spruce Biosciences | 14 | 2026-12-01 | 2026-09-21 |
Showing 20 of 4438. Sign in to see all of them.
Breast Neoplasms (1273) · Arthritis, Rheumatoid (451) · Psoriasis (265) · Dermatitis, Atopic (235) · Melanoma (181) · Acne Vulgaris (138) · Lupus Erythematosus, Systemic (119) · Arthritis, Psoriatic (105) · Triple Negative Breast Neoplasms (100) · Neoplasm Metastasis (90) · Eczema (85) · Pruritus (84) · Skin Diseases (83) · Arthritis, Juvenile (79) · Keratosis, Actinic (78)
Skin Diseases (3469) · Neoplasms (1637) · Neoplasms by Site (1559) · Breast Diseases (1337) · Immune System Diseases (1219) · Connective Tissue Diseases (1015) · Musculoskeletal Diseases (788) · Autoimmune Diseases (761) · Pathological Conditions, Signs and Symptoms (729) · Joint Diseases (659) · Arthritis (604) · Rheumatic Diseases (572) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (510) · Genetic Diseases, Inborn (473)
Cyclophosphamide (205) · Methotrexate (168) · Paclitaxel (167) · Docetaxel (154) · Capecitabine (135) · Trastuzumab (129) · Tamoxifen (114) · Letrozole (101) · tocilizumab (99) · Epirubicin (96) · Adalimumab (91) · Doxorubicin (84) · Anastrozole (73) · exemestane (72) · Fluorouracil (70)
Novartis Pharmaceuticals (158) · Hoffmann-La Roche (151) · Pfizer (98) · Amgen (78) · Eli Lilly and Company (78) · Bristol-Myers Squibb (64) · AstraZeneca (62) · AbbVie (59) · GlaxoSmithKline (52) · Fudan University (51) · Merck Sharp & Dohme LLC (50) · Galderma R&D (43) · Sanofi (43) · Alliance for Clinical Trials in Oncology (39) · Assistance Publique - Hôpitaux de Paris (38)
United States (1897) · Germany (1014) · Canada (963) · France (900) · Spain (841) · United Kingdom (790) · Poland (759) · Italy (753) · China (693) · Australia (607) · Hungary (529) · Belgium (526) · Japan (515) · South Korea (497) · Czechia (468)
PMID 38979716, PMID 34037241, PMID 32816215, PMID 27338778, PMID 33687069, PMID 36526796, PMID 36931693, PMID 29244149, PMID 30649524, PMID 34870800, PMID 36326435, PMID 36754548, PMID 40875187, PMID 29522361, PMID 33263165, PMID 36600185, PMID 36601090, PMID 39588375, PMID 28143815, PMID 33127856, PMID 36814062, PMID 37316690, PMID 37453736, PMID 37906417, PMID 37945286, PMID 37982966, PMID 25047021, PMID 33826132, PMID 33874971, PMID 34921355, PMID 38446397, PMID 40207789, PMID 42162528, PMID 30177460, PMID 34041702, PMID 34706874, PMID 35305260, PMID 35577477, PMID 36715850, PMID 37308218, PMID 38958913, PMID 39192350, PMID 40600584, PMID 40993471, PMID 22491018, PMID 26275429, PMID 29463520, PMID 29949132, PMID 30219772, PMID 30739254
2023 (123), 2016 (58), 2014 (51), 2018 (50), 2019 (48), 2015 (47), 2017 (45), 2009 (37), 2008 (31), 2005 (29), 2025 (29), 2004 (14), U10CA031946 (12), U10CA180868 (11), U10CA032102 (10)